Compare OVV & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVV | DVA |
|---|---|---|
| Founded | 2020 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Misc Health and Biotechnology Services |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.4B |
| IPO Year | N/A | 1995 |
| Metric | OVV | DVA |
|---|---|---|
| Price | $37.33 | $115.18 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 4 |
| Target Price | $49.50 | ★ $145.00 |
| AVG Volume (30 Days) | ★ 3.1M | 1.0M |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | ★ 5.63 |
| EPS | 0.90 | ★ 9.76 |
| Revenue | $8,794,000,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | N/A | $6.50 |
| Revenue Next Year | $1.65 | $2.97 |
| P/E Ratio | $41.52 | ★ $11.80 |
| Revenue Growth | N/A | ★ 5.14 |
| 52 Week Low | $29.80 | $113.97 |
| 52 Week High | $46.35 | $179.60 |
| Indicator | OVV | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 39.49 | 37.78 |
| Support Level | $37.05 | $115.91 |
| Resistance Level | $38.86 | $122.40 |
| Average True Range (ATR) | 1.15 | 2.58 |
| MACD | -0.54 | -0.05 |
| Stochastic Oscillator | 4.64 | 6.02 |
Ovintiv Inc is a North American oil and natural gas exploration and production company that is focused on developing its multi-basin portfolio of high-quality assets located in the United States and Canada. Its operations also include the marketing of oil, NGLs and natural gas. The company has two operating segments: USA Operations, and Canadian Operations. The USA Operations include the exploration for, development of, and production and marketing of oil, NGLs, natural gas and other related activities within the United States. The Canadian Operations include the exploration for, development of, and production and marketing of oil, NGLs, natural gas and other related activities within Canada.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.